CMO

Bio & Pharma Samsung Biologics bags $514 mn CMO contract from US pharma

Samsung Biologics Co., the world’s largest contract manufacturing organization (CMO), said on Monday it has secured a $5.14 million order from...

Bio & Pharma Samsung Biologics signs $1.4 bn CMO deal with European pharma

South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, said on Tuesday it signed a $1.4 billion contract manufacturing o...

Bio & Pharma Samsung’s biotech duo on a roll with $1.1 bn CMO order

Samsung Group is on track to rise to the top of biosimilar companies in the world and become South Korea’s largest drug maker for contract man...

Bio & Pharma Samsung Biologics reaches record-breaking annual orders

Samsung Biologics Co., the world’s top contract manufacturing organization (CMO) by capacity, surpassed the annual contract manufacturing orde...

Korean stock market KCGI Asset Management appoints former KIS head as new CMO

South Korea’s KCGI Asset Management, formerly Meritz Asset Management, announced on Friday that it has hired Cho Won-bok, former division head...

Bio & Pharma SK Bioscience buys 6.5 million Novavax shares for $83.4 million

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vacc...

Bio & Pharma Samsung Biologics bags $183 million CMO order from Pfizer

Samsung Biologics Co., the world’s No. 1 contract drug maker in terms of production capacity, has won a $182.7 million contract manufacturing ...

Bio & Pharma Brazil approves Celltrion Pharm’s syringe facility

Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...

Bio & Pharma Korea's Samsung Biologics signs $296 mn CMO deal with GSK

South Korea’s Samsung Biologics Co. has signed a $296.1 million deal to supply biopharmaceutical products to UK-based multinational pharma gia...

Bio & Pharma Samsung Biologics signs $81 mn CMO deal with Novartis

South Korea’s Samsung Biologics Co. has inked an $81 million contract manufacturing deal with Novartis, the world’s fifth-largest pharma...

COVID-19 SK seeks to make Pfizer, Merck COVID-19 pills in CMO deals

SK Inc., the investment and holding company of South Korea’s SK Group, is seeking to make COVID-19 treatment pills developed by Pfizer Inc. an...

Pharamaceuticals Korea’s Genome & Company aims US CMO market

South Korea’s microbiome medicine developer Genome & Company geared up for entering the U.S. market to boost profits and make inroads into...

COVID-19 CureVac may pick Korea as Asian base for COVID vaccine production

German biopharmaceutical company CureVac N.V. may choose South Korea as one of its global production bases for the COVID-19 vaccine following Korean...

Korean food SK acquires 70% stake in Yposkesi to jump into cell, gene CMO business

SK Inc., the holding and investment company of SK Group, South Korea’s third-largest conglomerate, has acquired a 70% stake in Yposkesi, a Fre...

Biopharma CMO Moderna deal shows Korea’s prowess as global hub for biopharma CMO

South Korea is emerging as a global hub for the contract manufacturing of biopharmaceuticals following its latest deal to procure COVID-19 vaccines ...

Mergers & Acquisitions SK in talks to buy French biologics contract manufacturer

SK Holdings is in the early stages of negotiations to acquire France’s biologic contract manufacturing organization (CMO) Yposkesi, in a move ...